Argenx' Vyvgart launch in CIDP picks up as the company barrels toward 10 indications by 2030

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth indications for the versatile medicine.